Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GDA | Q9Y2T3 | 2/20 | 0.33 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.33 |
| ▸ | XDH | P47989 | 2/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.31 |
| ▸ | HBB | P68871 | 1/20 | 0.31 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | PNP | P00491 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | DRD3 | P35462 | 1/20 | 0.31 |
| ▸ | PI4KA | P42356 | 1/20 | 0.31 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.31 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.31 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2030088 | 0.79 | KDM4E (0.31) | ALDH1A1TP53HPGDPTGS1HBB | |
| 2,6-Diaminopurine SCHEMBL24052 | 0.79 | GDA (0.48) | GDAPDPK1XDHUSP2ALDH1A1 | |
| 2,6-Diaminopurine SCHEMBL29444619 | 0.79 | GDA (0.48) | GDAPDPK1XDHUSP2ALDH1A1 | |
| 2,6-Diaminopurine SCHEMBL6423146 | 0.78 | GDA (0.47) | GDAPDPK1XDHUSP2ALDH1A1 | |
| 2,6-Diaminopurine SCHEMBL8757968 | 0.78 | GDA (0.47) | GDAPDPK1XDHUSP2ALDH1A1 | |
| SCHEMBL6545701 | 0.76 | GDA (0.34) | GDAPDPK1XDHUSP2ALDH1A1 | |
| SCHEMBL842437 | 0.76 | CSNK2A1 (0.36) | GDAPDPK1XDHUSP2ALDH1A1 | |
| Isoguanine SCHEMBL887740 | 0.76 | PARP1 (0.36) | GDAPDPK1XDHUSP2ALDH1A1 | |
| SCHEMBL8850 | 0.76 | GDA (0.33) | GDAPDPK1XDHUSP2ALDH1A1 | |
| SCHEMBL22700248 | 0.76 | GDA (0.33) | GDAPDPK1XDHUSP2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9777270-B2 | Methods and compositions for selecting siRNA of improved functionality | THERMO FISHER SCIENTIFIC INC. (US) | 2017-10-03 | — | — | US | disclosed |
| US-20160201058-A1 | METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY | DHARMACON, INC. | 2016-07-14 | — | — | US | disclosed |
| US-20070161591-A1 | Methods and compositions for treating neurological disease | UNIVERSITY OF MASSACHUSETTS (US) | 2007-07-12 | — | — | US | disclosed |
| EP-1791567-A2 | CHEMICALLY MODIFIED OLIGONUCLEOTIDES | Alnylam Pharmaceuticals Inc. (US) | 2007-06-06 | — | — | EP | disclosed |
| WO-2006020768-A2 | CHEMICALLY MODIFIED OLIGONUCLEOTIDES | ALNYLAM PHARMACEUTICALS, INC. (US) | 2006-02-23 | — | — | WO | disclosed |
| WO-2004001027-A1 | OLIGONUCLEOTIDE INHIBITORS OF MBD2/DNA DEMETHYLASE AND USES THEREOF | MCGILL UNIVERSITY (CA) | 2003-12-31 | — | — | WO | disclosed |
| US-6300320-B1 | OLIGONUCLEOTIDES HYBRIDIZED WITH NUCLEIC ACIDS FOR TREATMENT OF CANCER OF THE BLADDER, BONES, LUNGS OR CENTRAL NERVOUS SYSTEMS | ISIS PHARMACEUTICALS, INC. | 2001-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161591-A1 | Methods and compositions for treating neurological disease | SMN1; SMN2, CLN6, INA | GDA 629/4885PDPK1 2921/4885XDH 2041/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.